# Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer

> **NCT00040170** · PHASE2 · TERMINATED · sponsor: **Transgene** · enrollment: 50 (—)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **BIOLOGICAL:** MVA-MUC1-IL2

## Key facts

- **NCT ID:** NCT00040170
- **Lead sponsor:** Transgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (—)
- **Last updated:** 2006-11-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040170, "Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00040170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*